Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells

References

• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402 - 12; http://dx.doi.org/10.1038/nrm2395; PMID: 18431400
   PubMed Web of Science ®Google Scholar
• Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124:207 - 19; http://dx.doi.org/10.1016/j.cell.2005.10.043; PMID: 16413492
   PubMed Web of Science ®Google Scholar
• Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34:1514 - 21; http://dx.doi.org/10.1016/S0959-8049(98)00228-7; PMID: 9893622
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009; 8:2821 - 32; http://dx.doi.org/10.1158/1535-7163.MCT-09-0462; PMID: 19789217
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330 - 8; http://dx.doi.org/10.1038/nrc1074; PMID: 12724731
   PubMed Web of Science ®Google Scholar
• Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010; 17:901 - 11; http://dx.doi.org/10.1038/cdd.2010.35; PMID: 20379196
   PubMed Web of Science ®Google Scholar
• Ju J, Schmitz JC, Song B, Kudo K, Chu E. Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clin Cancer Res 2007; 13:4245 - 51; http://dx.doi.org/10.1158/1078-0432.CCR-06-2890; PMID: 17634554
   PubMed Web of Science ®Google Scholar
• Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 2011; 10:69 - 79; http://dx.doi.org/10.1158/1535-7163.MCT-10-0581; PMID: 21075910
   PubMed Web of Science ®Google Scholar
• Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299 - 303; http://dx.doi.org/10.1038/387299a0; PMID: 9153396
   PubMed Web of Science ®Google Scholar
• Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325 - 34; http://dx.doi.org/10.1016/S0092-8674(00)80416-X; PMID: 9363941
   PubMed Web of Science ®Google Scholar
• Jeyaraj S, O’Brien DM, Chandler DS. MDM2 and MDM4 splicing: an integral part of the cancer spliceome. Front Biosci (Landmark Ed) 2009; 14:2647 - 56; http://dx.doi.org/10.2741/3402; PMID: 19273224
   PubMed Web of Science ®Google Scholar
• Okoro DR, Rosso M, Bargonetti J. Splicing up mdm2 for cancer proteome diversity. Genes Cancer 2012; 3:311 - 9; http://dx.doi.org/10.1177/1947601912455323; PMID: 23150764
   PubMedGoogle Scholar
• Kalnina Z, Zayakin P, Silina K, Linē A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005; 42:342 - 57; http://dx.doi.org/10.1002/gcc.20156; PMID: 15648050
   PubMed Web of Science ®Google Scholar
• Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13:4107 - 14; PMID: 7686617
   PubMed Web of Science ®Google Scholar
• Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25 - 7; http://dx.doi.org/10.1016/S0014-5793(97)01480-4; PMID: 9450543
   PubMed Web of Science ®Google Scholar
• Rodriguez MS, Desterro JMP, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000; 20:8458 - 67; http://dx.doi.org/10.1128/MCB.20.22.8458-8467.2000; PMID: 11046142
   PubMed Web of Science ®Google Scholar
• García-Echeverría C, Chène P, Blommers MJ, Furet P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J Med Chem 2000; 43:3205 - 8; http://dx.doi.org/10.1021/jm990966p; PMID: 10966738
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844 - 8; http://dx.doi.org/10.1126/science.1092472; PMID: 14704432
   PubMed Web of Science ®Google Scholar
• Biderman L, Poyurovsky MV, Assia Y, Manley JL, Prives C. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Mol Cell Biol 2012; 32:1214 - 25; http://dx.doi.org/10.1128/MCB.06150-11; PMID: 22290440
   PubMed Web of Science ®Google Scholar
• Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 2005; 24:3411 - 22; http://dx.doi.org/10.1038/sj.emboj.7600812; PMID: 16163388
   PubMed Web of Science ®Google Scholar
• Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ Jr., Appella E, Anderson CW. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 2003; 278:37536 - 44; http://dx.doi.org/10.1074/jbc.M305135200; PMID: 12860987
   PubMed Web of Science ®Google Scholar
• Dumaz N, Meek DW. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 1999; 18:7002 - 10; http://dx.doi.org/10.1093/emboj/18.24.7002; PMID: 10601022
   PubMed Web of Science ®Google Scholar
• Yeh PY, Chuang SE, Yeh KH, Song YC, Chang LL, Cheng AL. Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 2004; 23:3580 - 8; http://dx.doi.org/10.1038/sj.onc.1207426; PMID: 15116093
   PubMed Web of Science ®Google Scholar
• Sun XX, Dai MS, Lu H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 2007; 282:8052 - 9; http://dx.doi.org/10.1074/jbc.M610621200; PMID: 17242401
   PubMed Web of Science ®Google Scholar
• Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281:1677 - 9; http://dx.doi.org/10.1126/science.281.5383.1677; PMID: 9733515
   PubMed Web of Science ®Google Scholar
• Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14:289 - 300; PMID: 10673501
   PubMed Web of Science ®Google Scholar
• Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000; 14:278 - 88; PMID: 10673500
   PubMed Web of Science ®Google Scholar
• Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med 1997; 3:441 - 51; PMID: 9260156
   PubMed Web of Science ®Google Scholar
• Okamoto K, Taya Y, Nakagama H. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett 2009; 583:2710 - 4; http://dx.doi.org/10.1016/j.febslet.2009.07.021; PMID: 19619542
   PubMed Web of Science ®Google Scholar
• Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 2003; 23:5113 - 21; http://dx.doi.org/10.1128/MCB.23.15.5113-5121.2003; PMID: 12860999
   PubMed Web of Science ®Google Scholar
• Liang X, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ. The role of wild-type p53 in cisplatin-induced Chk2 phosphorylation and the inhibition of platinum resistance with a Chk2 inhibitor. Chemother Res Pract 2011; 2011:715469; http://dx.doi.org/10.1155/2011/715469; PMID: 22312557
   PubMedGoogle Scholar
• Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252:1708 - 11; http://dx.doi.org/10.1126/science.2047879; PMID: 2047879
   PubMed Web of Science ®Google Scholar
• Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304 - 11; PMID: 1933891
   PubMed Web of Science ®Google Scholar
• Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984; 4:1689 - 94; PMID: 6092932
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998; 12:2831 - 41; http://dx.doi.org/10.1101/gad.12.18.2831; PMID: 9744860
   PubMed Web of Science ®Google Scholar
• Yuan JM, Li XD, Liu ZY, Hou GQ, Kang JH, Huang DY, Du SX. Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev 2011; 12:3465 - 9; PMID: 22471498
   PubMed Web of Science ®Google Scholar
• Mendonça LM, da Silva Machado C, Teixeira CC, de Freitas LA, Bianchi MdeL, Antunes LM. Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells. Neurotoxicology 2013; 34:205 - 11; http://dx.doi.org/10.1016/j.neuro.2012.09.011; PMID: 23036615
   PubMed Web of Science ®Google Scholar
• Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC, Vassilev LT. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004; 279:53015 - 22; http://dx.doi.org/10.1074/jbc.M410233200; PMID: 15471885
   PubMed Web of Science ®Google Scholar
• Tack LC, Wright JH. Altered phosphorylation of free and bound forms of monkey p53 and simian virus 40 large T antigen during lytic infection. J Virol 1992; 66:1312 - 20; PMID: 1310751
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11:3471 - 81; http://dx.doi.org/10.1101/gad.11.24.3471; PMID: 9407038
   PubMed Web of Science ®Google Scholar
• Chung YM, Park SH, Tsai WB, Wang SY, Ikeda MA, Berek JS, Chen DJ, Hu MC. FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat Commun 2012; 3:1000; http://dx.doi.org/10.1038/ncomms2008; PMID: 22893124
   PubMed Web of Science ®Google Scholar
• Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998; 281:1674 - 7; http://dx.doi.org/10.1126/science.281.5383.1674; PMID: 9733514
   PubMed Web of Science ®Google Scholar
• Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RCA, van der Houven van Oordt W, Hateboer G, van der Eb AJ, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15:5349 - 57; PMID: 8895579
   PubMed Web of Science ®Google Scholar
• Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK, Jochemsen AG. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2001; 2:1029 - 34; http://dx.doi.org/10.1093/embo-reports/kve227; PMID: 11606419
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang X. Mdm2 and MdmX partner to regulate p53. FEBS Lett 2012; 586:1390 - 6; http://dx.doi.org/10.1016/j.febslet.2012.02.049; PMID: 22673503
   PubMed Web of Science ®Google Scholar
• Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 1999; 274:38189 - 96; http://dx.doi.org/10.1074/jbc.274.53.38189; PMID: 10608892
   PubMed Web of Science ®Google Scholar
• Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999; 447:5 - 9; http://dx.doi.org/10.1016/S0014-5793(99)00254-9; PMID: 10218570
   PubMed Web of Science ®Google Scholar
• Jackson MW, Berberich SJ. MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 2000; 20:1001 - 7; http://dx.doi.org/10.1128/MCB.20.3.1001-1007.2000; PMID: 10629057
   PubMed Web of Science ®Google Scholar
• Stad R, Ramos YF, Little N, Grivell S, Attema J, van Der Eb AJ, Jochemsen AG. Hdmx stabilizes Mdm2 and p53. J Biol Chem 2000; 275:28039 - 44; PMID: 10827196
   PubMed Web of Science ®Google Scholar
• Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 2002; 277:19251 - 4; http://dx.doi.org/10.1074/jbc.C200150200; PMID: 11953423
   PubMed Web of Science ®Google Scholar
• Ray D, Murphy KR, Gal S. The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation. Cancer Biol Ther 2012; 13:848 - 57; http://dx.doi.org/10.4161/cbt.20835; PMID: 22785213
   PubMed Web of Science ®Google Scholar
• Huovinen M, Loikkanen J, Myllynen P, Vähäkangas KH. Characterization of human breast cancer cell lines for the studies on p53 in chemical carcinogenesis. Toxicol In Vitro 2011; 25:1007 - 17; http://dx.doi.org/10.1016/j.tiv.2011.03.018; PMID: 21457773
   PubMed Web of Science ®Google Scholar
• Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20:3224 - 33; http://dx.doi.org/10.1128/MCB.20.9.3224-3233.2000; PMID: 10757806
   PubMed Web of Science ®Google Scholar
• Zerbini LF, Wang Y, Correa RG, Cho JY, Libermann TA. Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 2005; 4:1247 - 53; http://dx.doi.org/10.4161/cc.4.9.1966; PMID: 16082226
   PubMed Web of Science ®Google Scholar
• Kaeser MD, Pebernard S, Iggo RD. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 2004; 279:7598 - 605; http://dx.doi.org/10.1074/jbc.M311732200; PMID: 14665630
   PubMed Web of Science ®Google Scholar
• Jagelská E, Brázda V, Pospisilová S, Vojtesek B, Palecek E. New ELISA technique for analysis of p53 protein/DNA binding properties. J Immunol Methods 2002; 267:227 - 35; http://dx.doi.org/10.1016/S0022-1759(02)00182-5; PMID: 12165443
   PubMed Web of Science ®Google Scholar
• Chandrachud U, Gal S. Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences. Technol Cancer Res Treat 2009; 8:445 - 53; PMID: 19925028
   PubMed Web of Science ®Google Scholar